- Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaWang, Langqi; Yang, Jilong; Jin, Bo; Wang, Bo; Zhou, Lijuan; Zhuo, Yaqi; Chen, Huifang; Chang, Lung-Ji; Tu, Sanfang; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective AnalysisWu, Shaojie; Tu, Sanfang; Zhou, Zhenjun; Sun, Xinlin; Wu, Anqin; Wang, Lei; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow upSong, Yuqin; Zhou, Keshu; Li, Dengju; Hu, Jianda; Zou, Dehui; Gao, Sujun; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lyu, Fangfang; Fang, Cheng; Xu, Sheng; Zhu, Jun65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Orelabrutinib Plus R-CHOP Regimen in Treatment-Naive Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)
20阅读
